{"contentid": 488772, "importid": NaN, "name": "UK reimbursement win for Tremfya in psoriatic arthritis", "introduction": "A positive reimbursement decision in the UK will enable Tremfya (guselkumab) to be offered for active psoriatic arthritis (PsA) through the country\u00e2\u0080\u0099s National Health Service (NHS).", "content": "<p><span style=\"font-weight: 400;\">A positive reimbursement decision in the UK will enable Tremfya (guselkumab) to be offered for active psoriatic arthritis (PsA) through the country&rsquo;s National Health Service (NHS).</span></p>\n<p><span style=\"font-weight: 400;\">The decision from the National Institute for Health and Care Excellence (NICE) covers treatment for eligible people who have not responded well to disease-modifying antirheumatic drug (DMARD) therapies or who cannot tolerate them.</span></p>\n<p><span style=\"font-weight: 400;\">The recommendation is based on results from the DISCOVER-1 and DISCOVER-2 Phase III clinical trials, data from which were published in The Lancet.</span></p>\n<p><span style=\"font-weight: 400;\">Developed by USA-based healthcare giant Johnson &amp; Johnson (NYSE: JNJ), Tremfya is the first approved fully-human monoclonal antibody that selectively binds to the p19 subunit of IL-23.</span></p>\n<p><span style=\"font-weight: 400;\">Sales of the product have grown steadily to reach blockbuster status, bringing in $1.3 billion for the firm in 2020, up from just over a billion dollars the year before.</span></p>\n<h2><strong>More options</strong></h2>\n<p><span style=\"font-weight: 400;\">Tremfya is the first interleukin (IL)-23 inhibitor to be approved as a treatment for PsA, and the firm said it would&nbsp; continue to collaborate with the NICE in an attempt to broaden access for a wider range of affected patients.</span></p>\n<p><span style=\"font-weight: 400;\">James Galloway, consultant rheumatologist at King's College Hospital, said the therapy would provide &ldquo;a new treatment option for eligible patients that offers both symptom control as well as protection from long term joint damage.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">He added: &ldquo;The recent NICE announcement is welcome news indeed, and a great addition to our existing treatment toolkit.&rdquo;</span></p>", "date": "2021-05-28 12:47:00", "meta_title": NaN, "meta_keywords": "Tremfya, reimbursement, psoriatic, arthritis, treatment, decision, National, Health, NICE, enable, guselkumab, active, positive, offered, Service, DISCOVER", "meta_description": "A positive reimbursement decision in the UK will enable Tremfya (guselkumab) to be offered for active psoriatic arthritis (PsA) through the country\u00e2\u0080\u0099s National H", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-28 12:46:18", "updated": "2021-05-28 16:05:05", "access": NaN, "url": "https://www.thepharmaletter.com/article/uk-reimbursement-win-for-tremfya-in-psoriatic-arthritis", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "johnson_big.jpg", "image2id": "johnson_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology, Pharmaceutical", "therapy area_tag": "Anti-Arthritics/Rheumatics", "topic_tag": "Focus On, Pricing, reimbursement and access, Research", "geography_tag": "UK, USA", "company_tag": "Johnson & Johnson", "drug_tag": "Tremfya", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-28 12:47:00"}